SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
Accounts Payable
SK Bioscience Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accounts Payable
₩17.8B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Payable
₩75.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
33%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Accounts Payable
₩4.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Accounts Payable
₩11.1B
|
CAGR 3-Years
56%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Payable
₩10B
|
CAGR 3-Years
92%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Accounts Payable?
Accounts Payable
17.8B
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Accounts Payable amounts to 17.8B KRW.
What is SK Bioscience Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-1%
Over the last year, the Accounts Payable growth was 429%. The average annual Accounts Payable growth rates for SK Bioscience Co Ltd have been -35% over the past three years , -1% over the past five years .
You don't have any saved screeners yet